Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    systematic_literature_reviews_whitepaper
    Demystifying the SLR: “S” stands for systematic

    A structured approach to evidence-based decision-making.

    biosimilars and oncology
    The future of oncology biosimilars

    Considerations for development through 2040.

    icons connected through network_artificail_intelligence
    Decoding AI in software as a medical device (SaMD)

    Regulatory insights and market strategies.

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Enhancing clinical trials in obesity by integrating COAs and DHTs

    7 October 2025. Register now.

    whitepaper CNS
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    22 October 2025. Register now.

  • About ICON
    About ICON
    Company history ICON at a glance Healthcare Intelligence ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Medical analytics presentation preview
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases
  4. ICON sponsored research validates shorter and simpler patient consent

ICON sponsored research validates shorter and simpler patient consent

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Research by Carnegie Mellon University shows reducing content on consent forms and using video can improve patient comprehension

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today welcomed the results of ICON-supported research at Carnegie Mellon University (CMU) which validate  a shorter, simple approach to patient consent processes.

The results, which were recently published in Medical Decision Making journal, show that patient consent forms could be shortened by up to 86% without losing critical understanding or sacrificing the content required by ethics boards. The research also found greater patient engagement when using a shorter paper form or when using a video format, compared with more traditional, paper-based approaches.

Academic researchers at CMU conducted a number of studies evaluating patient-centric and patient-designed informed consent formats.  In the first study, 118 asthma patients examined sections of a standard informed consent document for an asthma trial and then selected and ranked the information they deemed critical to their decision making.

In the second study, 83 asthma patients were randomly assigned to review either a full informed consent document; a shortened document, based on patient preferences from the first study; or a video that presented patient consent information in an animated format. The video was developed by ICON, using its Firecrest suite of multi-media solutions.

In the first study, patients identified a fraction of the content on a typical informed consent form as relevant to their deciding whether to participate in a trial. Their preferences led to a significantly (86%) shorter consent form, with greater emphasis on aspects that directly affected them (including trial procedures, potential side effects and benefits) and less attention to aspects that mattered less to them (e.g. privacy assurances, procedural information for clinical staff).

In the second study, participants who received the shortened paper form and video format absorbed as much information as participants receiving the long form, and described themselves as more engaged. Those receiving the video format rated themselves significantly higher scores on physician trust.

Commenting on the results of the CMU research, Dr. Lars-Olof Eriksson, EVP Site and Patient Recruitment, said: “Informed consent materials are very often long, complicated and too technical which is why we commissioned CMU to examine how a simpler, more patient-centric approach would affect patients’ understanding, confidence and trust. Through this research, patients have made their information needs and preferences very clear. We have already incorporated the CMU research findings into our Firecrest eConsent and Patient Portal solutions and we remain committed to developing further innovative solutions that drive better patient recruitment and engagement in clinical trials.”

ICON’s Firecrest Patient Portal is the patient’s gateway to clinical trials and has been specifically designed to enhance patients’ understanding of treatment before consenting to participate in a trial. Patients using the Patient Portal can find active trials, complete pre-screening questionnaires and watch educational videos in the comfort of their own homes, before choosing a convenient study location. The Patient Portal also includes a patient visit-by-visit guide, which informs patients about what to expect during site visits.

About ICON plc

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 89 locations in 37 countries and has approximately 12,200 employees. Further information is available at ICON.

ICON Media Contact

Cami Frederix
Weber Shandwick
+44 (0) 207 067 0272
CFrederix@webershandwick.com

In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?